Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EGFR Inhibitor HM61713

Known as: HM61713 
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non-small cell lung cancer. Tyrosine kinase… Expand
Is this relevant?
Review
2017
Review
2017
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.
9055Background: T790M mediates acquired resistance to 1st/2nd generation EGFR-TKIs. BI 1482694 is a 3rd generation TKI active… Expand
Is this relevant?
2016
2016
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.
s, ELCC 2016 Journal of Thoracic Oncology Vol. 11, Suppl. 4S (2016) S113–S142 
Is this relevant?
Review
2016
Review
2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs… Expand
  • table 2
  • table 3
  • table 3
  • figure 1
  • table 4
Is this relevant?
2016
2016
190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine…
effusion. There were 410 male and 120 female, with a mean age of 54 years. In 401 patients VATS was performed under general… Expand
Is this relevant?
2015
2015
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase…
8084 Background: HM61713 is an orally available EGFR mutation-specific inhibitor with sparing EGFR WT tumors that previously… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase…
8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations including both activating mutations and T790M… Expand
Is this relevant?
2014
2014
Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor
Introduction: Activating mutations of EGFR are well known as oncogenic driver mutations in lung adenocarcinoma. Currently, EGFR… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE